Uncategorized

In the tangled corridors of government oversight, Dr. Jeffrey E. Shuren was a prominent figure, heading the Food and Drug Administration’s medical device branch for more than a decade. Leading a team of about 2,500 people, Dr. Shuren oversaw an expansive budget of about $790 million, according to U.S. Senate Health, Education, Labor, and Pensions Committee documents. Dr. Shuren’s tenure has been marked by significant accomplishments, including record approvals of innovative medical devices ranging from joint replacements to infectious disease diagnostics. His leadership was recently praised by FDA Commissioner Dr. Robert Califf, who highlighted the historic number of new device…

In the dynamic landscape of Las Vegas, the term “break” often signals a deeper problem. The city has seen icons and performers step back, sometimes permanently, from the spotlight. That includes celebrities taking a break for makeovers or dropping shows when big events like the NFR come around. Recently, the “BattleBots – Destruct-A-Thon” show announced a temporary closure following its August 10 event, hinting at a possible end to its current format. The hiatus came as the Las Vegas Formula One Grand Prix scheduled events that inadvertently sidelined “BattleBots” for five weeks in 2023, mirroring a broader slowdown in ticket…

As the WNBA regular season nears its climax, the competition for playoff spots intensifies. Every team is jockeying for position, with less than a month left to solidify their position. Here's an in-depth look at the current contenders, analyzing their strengths, potential weaknesses, and key challenges. New York Liberty: Keeping the Pace The Liberty have exceeded all expectations this season, echoing the Aces' previous dominance. Their primary concern is maintaining their stellar performance under the increasing pressure of the playoffs and effectively managing player fatigue. Minnesota Lynx: Needs Interior Score Known for their prowess from beyond the arc, the Lynx’s…

In a recent long-term research study published Tuesday, Eli Lilly reported that its popular weight-management drug significantly reduced the incidence of type 2 diabetes by 94 percent among overweight or obese adults who had prediabetic symptoms, compared to a control group that received a placebo. The late-stage study explored the effects of tirzepatide, the active compound in both Eli Lilly’s Zepbound weight-loss shot and the diabetes treatment Mounjaro. Over about three years, participants who received the highest weekly dose of tirzepatide experienced an average reduction in body weight of 22.9 percent, while those who took a placebo saw only a…